Literature DB >> 9709296

Human papillomavirus infection and anogenital neoplasia in human immunodeficiency virus-positive men and women.

J M Palefsky1.   

Abstract

Human immunodeficiency virus (HIV)-positive women have a higher prevalence of human papillomavirus (HPV) infection in the cervix and anus, as well as squamous intraepithelial lesions (SILs) at these sites, than do HIV-negative women matched for age and HIV risk factors. Similarly, HIV-positive homosexual or bisexual men have a higher prevalence of anal HPV infection and anal SIL than do HIV-negative homosexual or bisexual men. In HIV-positive individuals, the prevalence of HPV infection, the proportion infected with multiple HPV types, and the prevalence of anogenital SILs increase with decreasing CD4 count. This situation may reflect loss of systemic immune response to HPV antigens or local HPV-HIV interactions at the tissue or cellular level. Despite the high levels of anogenital SILs, to date, there has not been a significant increase in reported cases of invasive anogenital cancer in HIV-positive individuals. However, several years may be required for SIL to progress to invasive cancer, and the advent of newer therapies for HIV that are expected to prolong survival may paradoxically increase the risk of progression to cancer in individuals with SILs if these lesions do not regress spontaneously and remain untreated.

Entities:  

Mesh:

Year:  1998        PMID: 9709296     DOI: 10.1093/oxfordjournals.jncimonographs.a024166

Source DB:  PubMed          Journal:  J Natl Cancer Inst Monogr        ISSN: 1052-6773


  32 in total

1.  The Interaction Between HIV and the Classic Sexually Transmitted Diseases.

Authors: 
Journal:  Curr Infect Dis Rep       Date:  2000-02       Impact factor: 3.725

Review 2.  Anal Intraepithelial Neoplasia and Squamous Cell Cancer of the Anus.

Authors:  Rebecca E Hoedema
Journal:  Clin Colon Rectal Surg       Date:  2018-11-02

Review 3.  Basic Science, Epidemiology, and Screening for Anal Intraepithelial Neoplasia and Its Relationship to Anal Squamous Cell Cancer.

Authors:  Kurt G Davis; Guy R Orangio
Journal:  Clin Colon Rectal Surg       Date:  2018-11-02

Review 4.  Screening, Surveillance, and Treatment of Anal Intraepithelial Neoplasia.

Authors:  Kevin C Long; Raman Menon; Amir Bastawrous; Richard Billingham
Journal:  Clin Colon Rectal Surg       Date:  2016-03

Review 5.  Human papillomavirus-related cervical and anal disease in HIV-infected individuals in the era of highly active antiretroviral therapy.

Authors:  Christophe Piketty; Michel D Kazatchkine
Journal:  Curr HIV/AIDS Rep       Date:  2005-08       Impact factor: 5.071

6.  Abstracts of the HIV Drug Therapy in the Americas 8-10 May 2014, Rio de Janeiro, Brazil.

Authors: 
Journal:  J Int AIDS Soc       Date:  2014-05-07       Impact factor: 5.396

7.  Individual and partner risk factors associated with abnormal cervical cytology among women in HIV-discordant relationships.

Authors:  Jason Soh; Anne F Rositch; Laura Koutsky; Brandon L Guthrie; Robert Y Choi; Rose K Bosire; Ann Gatuguta; Jennifer S Smith; James Kiarie; Barbara Lohman-Payne; Carey Farquhar
Journal:  Int J STD AIDS       Date:  2013-09-18       Impact factor: 1.359

8.  The impact of HIV viral control on the incidence of HIV-associated anal cancer.

Authors:  Elizabeth Y Chiao; Christine M Hartman; Hashem B El-Serag; Thomas P Giordano
Journal:  J Acquir Immune Defic Syndr       Date:  2013-08-15       Impact factor: 3.731

9.  Risk factors for anal human papillomavirus infection type 16 among HIV-positive men who have sex with men in San Francisco.

Authors:  Alexandra L Hernandez; Jimmy T Efird; Elizabeth A Holly; J Michael Berry; Naomi Jay; Joel M Palefsky
Journal:  J Acquir Immune Defic Syndr       Date:  2013-08-01       Impact factor: 3.731

10.  Impact of the HIV epidemic on the incidence rates of anal cancer in the United States.

Authors:  Meredith S Shiels; Ruth M Pfeiffer; Anil K Chaturvedi; Aimee R Kreimer; Eric A Engels
Journal:  J Natl Cancer Inst       Date:  2012-10-05       Impact factor: 13.506

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.